Table 7.
Compounds Codes | GPCR Ligand | Ion Channel Modulator | Kinase Inhibitor | Nuclear Receptor Ligand | Protease Inhibitor | Enzyme Inhibitor | Reported Target | Reference |
---|---|---|---|---|---|---|---|---|
Imidazole Derivatives as Anti-Cancer | ||||||||
C1 | −0.10 | −0.20 | 0.08 | −0.41 | −0.57 | −0.33 | Topoisomerase IIR catalytic inhibitors. | [9] |
C2 | −0.89 | −2.07 | −1.81 | −1.61 | −0.81 | −1.39 | ND | [10] |
C3 | 0.23 | 0.16 | 0.61 | −0.87 | 0.21 | 0.12 | Focal Adhesion Kinase (FAK) inhibition. | [12] |
C4 | 0.53 | 0.34 | 0.28 | −0.05 | 0.10 | 0.41 | ND | [14] |
C5 | −0.09 | −0.14 | −0.12 | −0.62 | −0.62 | −0.02 | Cyclin-dependent kinase 6 (CDK6) inhibition | [15] |
C6 | −0.20 | −0.23 | 0.41 | −0.59 | −0.48 | 0.25 | ND | [16] |
C7 | −0.13 | −0.64 | 0.03 | −0.46 | −0.52 | −0.18 | ND | [17] |
C8 | −0.16 | −0.27 | 0.13 | −0.48 | −0.33 | 0.06 | Inhibit tubulin polymerization | [21] |
C9 | −0.35 | −1.07 | −0.69 | −1.19 | −0.48 | −0.14 | ND | [22] |
C10 | 0.13 | 0.11 | 0.28 | −0.03 | −0.09 | 0.09 | ND Possibly due to dimerized estrogen receptor |
[18] |
C11 | 0.32 | 0.30 | 0.51 | −0.19 | −0.24 | 0.31 | c-MYC G-quadruplex DNA stabilizers | [19] |
C12 | 0.18 | −0.16 | 0.37 | −0.45 | −0.11 | 0.04 | Aurora kinase inhibition | [20] |
C13 | 0.12 | −0.47 | 0.13 | −0.30 | −0.07 | −0.07 | Inhibit BRAFV600E kinase | [23] |
C14 | −0.28 | −0.85 | −0.34 | −0.62 | −0.34 | −0.20 | Inhibit GSK-3β | [24] |
C15 | 0.35 | 0.16 | 0.20 | −0.04 | 0.20 | 0.29 | ND | [11] |
C16 | −0.86 | −1.08 | −1.15 | −1.02 | −1.16 | −0.60 | ND | [13] |
C17 | 0.12 | 0.04 | −0.15 | −0.38 | 0.03 | 0.00 | ND | [25] |